AUA 2016: Validation of a bone scan positivity risk table in non-metastatic castration-resistant prostate cancer - Session Highlights

San Diego, California ( A very interesting poster was presented in today’s Prostate cancer: advanced session at the AUA 2016 evaluating the bone scan positivity risk table in non-metastatic castration-resistant prostate cancer. Dr Daniel Moreira reminded all that the most common means to detect prostate cancer metastases remain a bone scan

The authors previously developed a prediction tool that assesses the risk of positive bone scan by PSA and PSA doubling time.  The authors sought to externally validate this tool by using data from a separate cohort of men diagnosed with castrate-resistant prostate cancer. The authors retrospectively examined 429 bone scans of 281 castrate resistant prostate cancer patients. Area under the curve (AUC), calibration plots and decision curve analysis were used to assess the performance of the prior model to predict a positive scan in the new cohort. 26% of the scans were found to be positive. Both PSA and PSA doubling time were correlated with positive bone scan on multivariable analysis. The previously developed risk table had an AUC of 0.735 to predict positive bone scan with excellent calibration and provided additional net benefit in the decision curve analysis.  The authors conclude that they were able to validate their model and the Use of the risk table may allow better tailoring of patients’ scanning to identify metastases early while minimizing over-imaging.

chart post13


Presented By: Daniel Moreira, MD

Written By: Miki Haifler MD. Fox Chase Cancer Center, Philadelphia, PA. at the 2016 AUA Annual Meeting - May 6 - 10, 2016 – San Diego, California, USA